Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade

Area of Science:

• Pharmacogenetics
• Drug Metabolism

Background:

• Debrisoquine hydroxylation exhibits polymorphic distribution in Caucasians.
• This study investigates the genetic basis of propranolol metabolism.

Purpose of the Study:

• To determine if 4-hydroxylation of propranolol is polymorphically distributed.
• To assess the relationship between debrisoquine metabolism and 4-hydroxypropranolol production.
• To evaluate the contribution of 4-hydroxypropranolol to propranolol's beta-blockade activity.

Main Methods:

• Assessed debrisoquine hydroxylation phenotypes.
• Measured 4-hydroxypropranolol production in individuals with different debrisoquine metabolic capacities.
• Compared plasma propranolol concentrations and beta-blockade extent between poor and extensive metabolizers.

Main Results:

• 4-hydroxylation of propranolol is polymorphically distributed and cosegregates with debrisoquine metabolism.
• Poor debrisoquine metabolizers produced significantly less 4-hydroxypropranolol.
• No significant differences in plasma propranolol levels or beta-blockade were observed between the groups.

Conclusions:

• 4-hydroxypropranolol is unlikely to be a major contributor to the beta-blocking effects of propranolol.
• Pharmacogenetic variations in debrisoquine metabolism influence 4-hydroxypropranolol production but not overall propranolol efficacy.